Online Exclusives

Online Exclusives

After Gene-Editing Uproar, China Poised to Adopt New Regulation

China is on the brink of adding human genes and embryos to the section of its civil code that protects personality rights, such as...

Venetoclax Approved for CLL and SLL

The FDA approved venetoclax, in combination with obinutuzumab, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The...

House Supports Health Care Legislation That Strengthens the Affordable Care Act

In a 234-to-183 vote, the U.S. House of Representatives passed legislation to rein in the high costs of prescription drugs and to bolster elements...

FDA Approves First Anticoagulant for Pediatric Patients

The U.S. Food and Drug Administration (FDA) approved dalteparin sodium, administered as a subcutaneous injection, to reduce the recurrence of symptomatic venous thromboembolism (VTE)...

FDA’s ODAC Recommends Against Approval of Quizartinib for AML

In an 8-to-3 vote, the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drug Advisory Committee (ODAC) decided against recommending approval of quizartinib for patients...

Japan Sets $306,000 Price for Tisagenlecleucel

The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel was approved for use in Japan in March 2019, and a government panel recently set the...

Quality of Generic Drugs Manufactured Overseas Comes into Question

The passage of the Hatch-Waxman Act in 1984, which created a regulatory track for generic drugs, marked the beginning of the generic-drug boom in...

Who Foots the Surprise Bill?

As U.S. Senators prepare for a July vote on proposed legislation that would protect patients from surprise medical bills, three key players in the...

More Than 40 States File Suit Against Generic Drug Manufacturers

Forty-three states and Puerto Rico have filed a lawsuit against 20 of the largest U.S. generic drug manufacturers. They allege that the companies manipulated...

Benchmarking Drug Prices Could Save the U.S. Billions on Medicare Part D

The U.S. could save billions by pegging drug prices to what other countries pay, according to a new study in Health Affairs. The research indicates...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.